Analisis Keuangan Saham NRXPW - NRx Pharmaceuticals, Inc.

Gambaran Umum

NRx Pharmaceuticals, Inc., headquartered in the United States, operates prominently within the pharmaceutical industry. The company is dedicated to pioneering novel therapies, focusing on mental health disorders and inflammatory diseases. A pivotal project undertaken by NRx Pharmaceuticals is the development of Cyclurad, a treatment designed for suicidal bipolar depression, which is an innovation underpinned by intellectual property and strategic collaborations with academic and medical institutions. Another significant initiative focuses on addressing critical care therapies for lung injury and cytokine storm syndrome related to COVID-19, demonstrating the company's commitment to responding to urgent global health crises. NRx Pharmaceuticals continues to evolve its research and clinical trials to meet complex healthcare challenges, leveraging cutting-edge science and strategic partnerships.

Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih

Nilai operating income untuk NRx Pharmaceuticals, Inc. - Equity Warrant per 2025 Jun 30 adalah -14.13 MM.
Nilai net income untuk NRx Pharmaceuticals, Inc. - Equity Warrant per 2025 Jun 30 adalah -33.79 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-14.13	-33.79
2025-03-31		-17.45	-24.11
2024-12-31		-19.70	-25.13
2024-09-30		-20.48	-20.38
2024-06-30		-23.26	-24.82
2024-03-31		-24.15	-25.64
2023-12-31		-27.59	-30.15
2023-09-30		-33.07	-36.06
2023-06-30		-36.40	-39.08
2023-03-31		-38.06	-37.34
2022-12-31		-44.34	-39.75
2022-09-30		-87.42	-59.92
2022-06-30		-98.38	-87.89
2022-03-31		-105.90	-81.02
2021-12-31		-94.43	-93.06
2021-09-30		-47.09	-107.78
2021-06-30		-32.14	-75.90
2021-03-31		-14.92	-75.68
2020-12-31		-11.90	-51.78
2020-09-30		-7.80	-8.31

Laporan Laba Rugi: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Arus Kas: Operasi, Investasi, Pendanaan

Nilai cash from operating activities untuk NRx Pharmaceuticals, Inc. - Equity Warrant per 2025 Jun 30 adalah -11.91 MM.
Nilai kas dari aktivitas pendanaan untuk NRx Pharmaceuticals, Inc. - Equity Warrant per 2025 Jun 30 adalah 12.92 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-11.91		12.92
2025-03-31	-10.45		14.68
2024-12-31	-10.64		7.49
2024-09-30	-11.73	0.00	4.47
2024-06-30	-13.99	-0.00	0.92
2024-03-31	-19.24	0.00	4.05
2023-12-31	-21.66	-0.00	6.20
2023-09-30	-26.78	-0.00	17.44
2023-06-30	-28.48	-0.01	18.91
2023-03-31	-35.46	-0.01	11.78
2022-12-31	-39.76	-0.01	32.21
2022-09-30	-42.72	-0.01	22.09
2022-06-30	-48.47	-0.01	59.64
2022-03-31	-45.07	-0.01	72.01
2021-12-31	-37.70	-0.01	63.46
2021-09-30	-26.83	-0.01	64.44
2021-06-30	-15.95	-0.01	28.34
2021-03-31	-4.45	-0.00	17.45
2020-12-31	-2.27	-0.00	3.25
2020-09-30	-2.90	-0.00	2.27

Metrik Penilaian: PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Metrik Penilaian: EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Efektivitas Manajemen

roa untuk NRx Pharmaceuticals, Inc. - Equity Warrant pada 2025 Jun 30 adalah -4.58.

Period End (TTM)	ROA	ROE	ROIC (Tingkat Pengembalian Investasi Modal)	CROIC	OCROIC
2025-06-30	-4.58
2025-03-31	-6.36
2024-12-31	-3.43
2024-09-30	-1.55
2024-06-30	-1.18
2024-03-31		-4.07
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31		0.00
2021-12-31
2021-09-30	0.00
2021-06-30	-93.10		-133.77	18.06	-23.24
2021-03-31	-76.76		-10.71	1.84	-0.63
2020-12-31	-52.52
2020-09-30

Gross Margins

Margin Kotor: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Margin Keuntungan Bersih: Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.

Margin Operasi: Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.

Period End (TTM)	Margin Kotor	Margin Keuntungan Bersih	Margin Operasi
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30

Analisis Keuangan Saham NRXPW - NRx Pharmaceuticals, Inc. - Equity Warrant (NasdaqCM) Stock